drugset / Trial / NCT05152303
A Study of Remimazolam Tosilate for Sedation in the ICU
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to explore the optimal dose regimen of Remimazolam Tosilate for Injection for sedation in the ICU, as well as preliminarily evaluate the efficacy and safety of Remimazolam Tosilate for Injection for sedation in the ICU.
Timeline
- Start
- 2022-10-12
- Primary completion
- 2023-04-02
- Completion
- 2023-04-19
Publications
- Liu N, Lin F, Wen J, Yu X, Zhou F, Yu Z, Yang M, Yu L, Lv A, Sun Y, Shen F, He B, Hu Z, Yin T, Li X, Zhao H, Wu J, Chen C, Nie Y, Zuo L, Guan X, Chen M. Efficacy and safety of remimazolam tosylate for sedation in ICU patients: A multicenter, randomized, phase 2 study. J Intensive Med. 2026 Mar 28;6(3):247-254. doi: 10.1016/j.jointm.2026.01.009. eCollection 2026 Jun.
- Liu N, Jiang Z, Nie Y, Zuo L, Chen C, Si X, Liu Q, Chen M, Guan X. Study Protocol of a Multicenter, Randomized, Single-Blind Trial: Efficacy and Safety of Remimazolam Tosylate for Sedation in ICU Patients. Adv Ther. 2023 May;40(5):2524-2533. doi: 10.1007/s12325-023-02456-7. Epub 2023 Mar 15.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remimazolam | Small molecule | — | Intravenous |
| Background | Propofol | Small molecule | — | Intravenous |
Indications
No indication recorded.